STLN · Starling Oncology, Inc. · Metrics
$3.26
+0.06 (+1.88%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$326.37M
Shares
101.99M
Volume · Nov 18
4.68M
Avg daily vol (3M)
2.45M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
STLN metrics
82 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$3.20
Market cap
$326.37M
Price action
23 metricsPrice change (1W)
-23.8%
Price change (30D)
-50.5%
Price change (3M)
-52.0%
Price change (6M)
-23.8%
Price change (YTD)
-10.1%
Price change (1Y)
-15.1%
Trailing year
Price change (5Y)
-61.0%
52-week high
$7.05
52-week low
$2.39
Change from 52-week high
-54.6%
Change from 52-week low
+34.2%
Annualized volatility
89.0%
Annualized volatility (3M)
112.6%
Implied volatility (30D)
71.7%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.5
RSI (14D)
27.7
Price vs SMA 50
-47.2%
Price vs SMA 200
-33.2%
Avg volume (3M)
2.45M
Relative volume
1.9
Average dollar volume
$12.16M
Company
3 metricsSector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
101.99M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.6×
reciprocal yield 171.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 190.1%
P / book
—
FCF yield
5.8%
TTM · current market cap
Buyback yield
—
P / FCF
17.3
reciprocal yield 5.8%
P / operating cash flow
14.1
reciprocal yield 7.1%
Earnings yield
-10.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-11-05
Profitability
9 metricsGross margin
—
Operating margin
-3.4%
Trailing 12 months
Net margin
-5.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$21.02M
Net income (TTM)
−$35.54M
Trailing 12 months
Diluted EPS (TTM)
$-0.27
FCF margin
3.0%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+24.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$620.45M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.4%
Year over year · more shares
Revenue CAGR (3Y)
+25.8%
Revenue CAGR (5Y)
+21.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-18.9%
Debt / equity
—
Current ratio
1.1
EBITDA (TTM)
−$14.41M
Free cash flow (TTM)
$18.83M
Quick ratio
0.8
Interest coverage
-2.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$35.62M
Latest balance sheet
Cash & equivalents
$36.90M
Total assets
$187.77M
Total debt
$72.52M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$23.10M
Capital expenditures (TTM)
$4.27M
R&D (TTM)
—
SG&A (TTM)
$118.33M
Stock compensation (TTM)
$5.42M
R&D / revenue
—
Stock compensation / revenue
0.9%
Ownership (13F)
9 metrics13F filers
130
13F filer change QoQ
+11
Institutional ownership
46.2%
Conviction holders (share of 13F filers)
2.3%
Crowding (high-turnover and private-fund holders)
16.0%
Private-fund adviser ownership
14.9%
Active holders' share change QoQ
+11.6%
Holder tenure
8.6
Price vs estimated holder cost
+43.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
9.1%
Short interest
3 metricsShort interest
6.7%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
64 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.95M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1799191
CUSIP
68236X100
13F (30d)
140 filings
127 filers
Visit website
Investor relations